An effective age‐unrestricted m‐AMSA‐based second‐line regimen for poor prognosis acute myeloid leukaemia

Abstract

Abstract:  The efficacy and toxicity of a regimen consisting of amsacrine (m‐AMSA), cytarabine, and thioguanine for remission‐induction therapy in poor prognosis categories of acute myeloid leukaemia (AML) were determined in a single arm study of 46 patients. The study group consisted of 17 patients with disease refractory to daunorubicin plus cytarabine‐based induction regimens, 22 patients with disease which had relapsed during daunorubicin plus cytarabine maintenance therapy, or following completion of this maintenance programme after receiving > 500 mg daunorubicin/m2, and 7 previously untreated patients where cardiac disease contraindicated anthracycline therapy. Complete remission (CR)..